Trilaciclib with immunotherapy and chemo for early TNBC
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have newly diagnosed triple-negative breast cancer that is locally advanced (stage T1c N1-3 or T2-4 N0-3).
- You are scheduled to receive chemotherapy before surgery (neoadjuvant therapy).
- You have not had any previous chemotherapy, immunotherapy, or other systemic treatment for your cancer.
- Your overall health is good (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. It’s for patients who are starting treatment for the first time and can safely receive pre-surgery chemotherapy.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests adding toripalimab (an immunotherapy drug) to chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.